It participated as a driver in tumorigenesis, tumor progression, and chemoresistance.[17] Also, FGFR1 signaling was described to contribute to epithelial‐to‐mesenchymal transition (EMT)‐associated acquired resistance of 1st and 2nd EGFR‐TKIs,[18] which provided a bypass protective mechanism after prolonged exposure to pharmacological‐inhibited EGFR signaling. The gene discussed is FGFR1; the disease is neoplasm.